ACT2 Project
THE UNIVERSITY OF BIRMINGHAM · Awarded
- Buyer
- THE UNIVERSITY OF BIRMINGHAM
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Professional Services
- Reference
- FaT-ocds-h6vhtk-0457fb
- Published
- 2024-05-08
- Deadline
- 2026-04-19
Tender summary
University of Birmingham (UoB) is the sponsor of ACT2 (Allogeneic Chondrocyte Therapy - A phase 2a study), an MRC funded project (MR/V027670/1). The study commenced in 2021 with the aim to develop and manufacture an allogeneic chondroprogenitor cell therapy from fresh osteochondral allografts in order to treat cartilage lesions in a single surgery. The study requires a manufacturing facility that can work with the research team to develop and validate the manufacturing process of the cell therapy product to a standard that can gain MHRA approval and thus enable the commencement of a Phase 2a…
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access